Related Experiment Video

Updated: Apr 18, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types

Kelly Lamiman1, Jill M Keller1, Atsushi Mizokami2

  • 1Department of Urology and Pathology, University of Michigan, Ann Arbor, Michigan.

Critical Reviews in Oncogenesis
|January 20, 2015
PubMed

Insights

Raf kinase inhibitor protein (RKIP) loss is common in solid tumors and predicts poor patient outcomes. This protein

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Raf kinase inhibitor protein (RKIP) is a known inhibitor of multiple signaling pathways.
  • RKIP exhibits metastasis suppressor gene activity and promotes apoptosis.
  • Loss of RKIP expression is frequently observed during cancer progression across various tumor types.

Purpose of the Study:

  • To review tumor types where RKIP function or expression has been evaluated.
  • To focus on RKIP expression in clinical tissues and its prognostic significance.
  • To assess RKIP as a potential prognostic biomarker in solid tumors.

Main Methods:

  • Conducted a PubMed literature search up to May 2014.
  • Identified 56 publications reporting RKIP expression in clinical cancer tissues.
  • Analyzed the correlation between RKIP expression and patient survival, metastasis, tumor grade, and stage.

Main Results:

  • Loss of RKIP expression demonstrated prognostic value for overall survival, disease-free survival, and metastasis in most solid tumors.
  • RKIP expression correlated with tumor grade or stage in approximately 50% of the reviewed studies.
  • RKIP loss is a frequent event in many solid tumor cancers.

Conclusions:

  • RKIP loss is a common finding in various solid tumors.
  • Reduced RKIP expression serves as a significant prognostic biomarker for adverse outcomes.
  • RKIP warrants further investigation as a predictive marker in clinical oncology.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.2K